A study, conducted by researchers from the AIDS Study Group (Gesida) of the Spanish Society of Infectious Diseases and Clinical Microbiology, whose objective was to compare the effects of strategies to simplify antiretroviral treatment (ART), to less than three drugs. After the study, they emphasize that the option of using a therapy based on a single antiretroviral (monotherapy) against HIV is associated with an increased risk of virological failure, defining it in at least two consecutive viral loads (biterapia) over 50. copies of the virus for each milliliter of blood (this is the figure established as undetectable and non-transferable viral load). These differences were not seen with the guidelines based on two drugs.
The work presented this week in Seattle (USA), where the Conference on Retroviruses and Opportunistic Infections (CROI) was held, consisted of a selection of patients who began treatment with triple therapy over the years 2004 and 2017, achieving an undetectable viral load in the first 48 weeks of treatment and staying in triple therapy throughout its follow-up and then simplifying to double and later to monotherapy.
The study included 8,416 people of whom 7,665 remained in triple therapy, 424 switched to biterapia and 327 to monotherapy. Simplification of antiretroviral therapy to monotherapy, but not to biterapia, was directly associated with an increased risk of virological failure.